{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kao C"],"funding":["U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)","NCI NIH HHS","NIH HHS"],"pagination":["3531"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12012091"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(1)"],"pubmed_abstract":["Most new cancer diagnoses occur in patients over the age of 65. The composition and function of the immune system changes with age, but how the aged immune system affects responses to immune checkpoint inhibitor (ICI) cancer therapies remains incompletely understood. Here, using multiplex cytokine assay and high-parameter mass cytometry, we analyze prospectively collected blood samples from 104 cancer patients receiving ICIs. We find aged patients ( ≥ 65-years-old; n = 54) derive similar clinical outcomes as younger patients (n = 50). However, aged, compared to young, patients have divergent immune phenotypes at baseline that persist during ICI therapy, including diminished cytokine responses, reduced pools of naïve T cells with increased relative expression of immune checkpoint molecules,"],"journal":["Nature communications"],"pubmed_title":["Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors."],"pmcid":["PMC12012091"],"funding_grant_id":["P01 CA247886","P30 CA006973","R01 CA293602","R21 CA264004","R01 CA197296","P50CA221707","S10 OD034407","P50 CA221707","P50 CA062924"],"pubmed_authors":["Bansal S","Griffin E","Ho WJ","Ged Y","Leatherman JM","Mohindra R","Jaffee EM","Kao C","Tang L","Lipson EJ","Kartalia E","Shu DH","Chandler GS","Coyne EM","Gross NE","Nakazawa M","Zabransky DJ","Hallab E","Alden S","Aziz K","Charmsaz S","Hernandez AG","Baretti M","Thoburn C","Hoffman-Censits J","Tsai HL","Munjal K","Li HL","Brancati M","Yarchoan M"],"additional_accession":[]},"is_claimable":false,"name":"Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors.","description":"Most new cancer diagnoses occur in patients over the age of 65. The composition and function of the immune system changes with age, but how the aged immune system affects responses to immune checkpoint inhibitor (ICI) cancer therapies remains incompletely understood. Here, using multiplex cytokine assay and high-parameter mass cytometry, we analyze prospectively collected blood samples from 104 cancer patients receiving ICIs. We find aged patients ( ≥ 65-years-old; n = 54) derive similar clinical outcomes as younger patients (n = 50). However, aged, compared to young, patients have divergent immune phenotypes at baseline that persist during ICI therapy, including diminished cytokine responses, reduced pools of naïve T cells with increased relative expression of immune checkpoint molecules,","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2025-07-01T03:05:20.081Z","creation":"2025-07-01T03:05:20.081Z"},"accession":"S-EPMC12012091","cross_references":{"pubmed":["40258833"],"doi":["10.1038/s41467-025-58512-z"]}}